The Cytokine response is a major problem in MANY autoimmune diseases . Your list is longer than you think of possible applications and areas for ongoing research. There are any scholarly articles on cytokines and autoimmune diseases . Drugs currently available come with awful side effects . This is an area of further research to require more effective targeting at any stage of the illness requiring a huge heap of money that I just do not see MSB having given the expense and time for trials. It would require a takeover by a major player or some sort of partnering. Anyway its all good for the share price.
Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease, page-110
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.25 |
Change
-0.055(4.21%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $18.18M | 14.71M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 123307 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 39491 | 12 |
View Market Depth
| Last trade - 15.03pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |